ABL Diagnostics strengthens its global leadership in HIV genotyping with DeepChek® Whole Genome HIV
Summary
ABL Diagnostics validated and publicized its DeepChek® Whole Genome HIV solution, reinforcing its position in HIV genotyping. The offering now forms part of a 10-solution HIV genotyping portfolio that combines kits and bioinformatics software for clinical labs, research centers, public health institutions, and pharma. DeepChek® Whole Genome HIV covers the GAG region to detect resistance mutations relevant to new therapeutic classes (e.g., lenacapavir), supports viral RNA and proviral DNA including whole blood, and demonstrates analytical sensitivity down to about 800 copies/mL. ABL verified DeepChek® compatibility across major NGS platforms (Illumina, MGI, Oxford Nanopore, PacBio, Thermo Fisher) and cited a new Journal of Clinical Virology publication supporting whole-genome sequencing clinical utility; the release is marked for research use only (RUO).
Classifications
AskAI Classifications
LabelsLinked Companies
